Table 3.
Clinical characteristics between PARP1 low and high expression groups
| Characteristic | Total (n = 72) | PARP1 expression | PARP1 expression | P-value |
|---|---|---|---|---|
| Low | High | |||
| Age (year) | 0.238 | |||
| < 55 | 36 (50.0) | 21 (29.2) | 15 (20.8) | |
| ≥ 55 | 36 (50.0) | 15 (20.8) | 21 (29.2) | |
| FIGO stage (2014) | 0.710 | |||
| I and II | 8 (11.1) | 3 (4.2) | 5 (6.9) | |
| III and IV | 64 (88.9) | 33 (45.8) | 31 (43.1) | |
| Diameter (cm) | 0.813 | |||
| < 8 | 40 (55.6) | 19 (26.4) | 21 (29.2) | |
| ≥ 8 | 32 (44.4) | 17 (23.6) | 15 (20.8) | |
| Ascitic fluid | 0.312 | |||
| Yes | 23 (31.9) | 9 (12.5) | 14 (19.4) | |
| NO | 49 (68.1) | 27 (37.5) | 22 (30.6) | |
| CA125 (U/ml) | 0.115 | |||
| < 35 | 4 (5.6) | 0 (0.0) | 4 (5.6) | |
| ≥ 35 | 68 (94.4) | 36 (50.0) | 32 (44.4) | |
| PD-L1 expression | 0.341 | |||
| Low | 41 (56.9) | 23 (31.9) | 18 (25.0) | |
| High | 31 (43.1) | 13 (18.1) | 18 (25.0) | |
| CD8 expression (cancer tissue) | 0.240 | |||
| Low | 38 (52.8) | 17 (23.6) | 21 (29.2) | |
| High | 34 (47.2) | 19 (26.4) | 15 (20.8) | |
Values are n (%)
FIGO, International Federation of Gynecology and Obstetrics; CA125, carbohydrate antigen; PARP1, poly-ADP-ribose polymerase 1; PD-L1, programmed death ligand 1